{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:31:08Z","timestamp":1794007868518,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Womens Ment Health"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purpose of the study is to examine the switching pattern and dose adjustment of antidepressants (ADs) prescribed to women from six months before to six months during pregnancy in the Netherlands. The recorded dispenses or refills were collected from the University of Groningen IADB.nl pregnancy subset for all singleton pregnancies in which the mother received \u2265 1 prescription of an AD dispensed before pregnancy and was present in the database at least six months after conception. The rates of continuation, discontinuation, and switching between 2001 and 2020 were assessed for the ADs studied. The mean number of Defined Daily Doses (DDDs) of the most frequently continued ADs used was calculated both before and during pregnancy, and a paired <jats:italic>t<\/jats:italic>-test was used to test for significant changes. The continuation rates for AD users, especially for SSRI and SNRI continued users, increased over time from 27% and 19% (2001\u20132005) to 65% and 65% (2016\u20132020). The switching rate between ADs remained consistently low from the start of the study (2001\u20132005) at 2.0% to the end of the study (2016\u20132020) at 2.3%. Most women who switched between antidepressants during pregnancy received a different SSRI monotherapy (85%), followed by an SNRI (6%), a TCA (4%), and an \u201cother AD\u201d (4%). In most cases observed, the dose adjustment for the mean DDDs during pregnancy compared to the mean DDDs before pregnancy only changed little (less than 10%). Continued use of SSRIs among singleton pregnancies doubled over the study period. The low rate of AD switching and little changes in the DDD adjustment for most AD continuers indicate that pregnant women prefer to continue their prepregnancy medication rather than switch it. Most observed findings cohere with the Dutch national guidelines for antidepressant use during pregnancy.<\/jats:p>","DOI":"10.1007\/s00737-023-01355-8","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T13:01:38Z","timestamp":1691240498000},"page":"685-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Switching pattern and dose adjustment of antidepressants before and during pregnancy"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-6785","authenticated-orcid":false,"given":"Robiyanto","family":"Robiyanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens H J","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-7210","authenticated-orcid":false,"given":"Eelko","family":"Hak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2236-1398","authenticated-orcid":false,"given":"Eug\u00e8ne P","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-2608","authenticated-orcid":false,"given":"Catharina C M","family":"Schuiling-Veninga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,5]]},"reference":[{"key":"1355_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1097\/AOG.0B013E31816FD910","volume":"111","author":"ACOG","year":"2008","unstructured":"ACOG (2008) ACOG Practice Bulletin no. 92: Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 111:1001\u20131020. https:\/\/doi.org\/10.1097\/AOG.0B013E31816FD910","journal-title":"Obstet Gynecol"},{"key":"1355_CR2","doi-asserted-by":"publisher","unstructured":"Arroll B, Elley CR, Fishman T et al (2009) Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007954","DOI":"10.1002\/14651858.CD007954"},{"key":"1355_CR3","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/bcp.13608","volume":"84","author":"A B\u00e9nard-Laribi\u00e8re","year":"2018","unstructured":"B\u00e9nard-Laribi\u00e8re A, Pambrun E, Sutter-Dallay AL et al (2018) Patterns of antidepressant use during pregnancy: a nationwide population-based cohort study. Br J Clin Pharmacol 84:1764\u20131775. https:\/\/doi.org\/10.1111\/bcp.13608","journal-title":"Br J Clin Pharmacol"},{"key":"1355_CR4","unstructured":"Bijwerkingen Centrum Lareb (2021a) SSRIs during pregnancy. https:\/\/www.lareb.nl\/mvm-kennis-pagina?id=71. Accessed 11 Sep 2022"},{"key":"1355_CR5","unstructured":"Bijwerkingen Centrum Lareb (2021b) Various antidepressants during pregnancy. https:\/\/www.lareb.nl\/mvm-kennis-pagina?id=108&naam=Diverse+antidepressiva+tijdens+de+zwangerschap. Accessed 23 Oct 2022"},{"key":"1355_CR6","unstructured":"Bijwerkingen Centrum Lareb (2022) SNRIs in anxiety and depressive symptoms during pregnancy. https:\/\/www.lareb.nl\/mvm-kennis-pagina?id=73&naam=SNRI%27s+bij+angst-+en+depressieve+klachten+tijdens+de+zwangerschap. Accessed 11 Sep 2022"},{"key":"1355_CR7","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1136\/BMJ.308.6942.1499","volume":"308","author":"JM Bland","year":"1994","unstructured":"Bland JM, Altman DG (1994) Statistic notes: regression towards the mean. BMJ 308:1499. https:\/\/doi.org\/10.1136\/BMJ.308.6942.1499","journal-title":"BMJ"},{"key":"1355_CR8","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1111\/bcp.13732","volume":"84","author":"P Damkier","year":"2018","unstructured":"Damkier P, Christensen LS, Broe A (2018) Patterns and predictors for prescription of psychotropics and mood-stabilizing antiepileptics during pregnancy in Denmark 2000-2016. Br J Clin Pharmacol 84:2651\u20132662. https:\/\/doi.org\/10.1111\/bcp.13732","journal-title":"Br J Clin Pharmacol"},{"key":"1355_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/ajo.13352","volume":"61","author":"S Donald","year":"2021","unstructured":"Donald S, Sharples K, Barson D et al (2021) Antidepressant dispensing before, during, and after pregnancy in New Zealand, 2005-2014. Aust N Z J Obstet Gynaecol 61:837\u2013845. https:\/\/doi.org\/10.1111\/ajo.13352","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"1355_CR10","doi-asserted-by":"publisher","unstructured":"Folsche T, Maier HB, Hillemacher T, Frieling H (2021) Combination therapies and switching of agents in depression and bipolar disorders. NeuroPsychopharmacotherapy:1\u201317. https:\/\/doi.org\/10.1007\/978-3-319-56015-1_437-1\/COVER","DOI":"10.1007\/978-3-319-56015-1_437-1\/COVER"},{"key":"1355_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/JCP.0B013E31818D2048","volume":"28","author":"MP Freeman","year":"2008","unstructured":"Freeman MP, Nolan PE, Davis MF et al (2008) Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol 28:646\u2013653. https:\/\/doi.org\/10.1097\/JCP.0B013E31818D2048","journal-title":"J Clin Psychopharmacol"},{"key":"1355_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/S41540-020-00157-3","volume":"6","author":"B George","year":"2020","unstructured":"George B, Lumen A, Nguyen C et al (2020) Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy. NPJ Syst Biol Appl 6:36. https:\/\/doi.org\/10.1038\/S41540-020-00157-3","journal-title":"NPJ Syst Biol Appl"},{"key":"1355_CR13","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/S00228-021-03122-Z","volume":"77","author":"E Heinonen","year":"2021","unstructured":"Heinonen E, Blennow M, Blomdahl-Wetterholm M et al (2021) Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low. Eur J Clin Pharmacol 77:1323\u20131331. https:\/\/doi.org\/10.1007\/S00228-021-03122-Z","journal-title":"Eur J Clin Pharmacol"},{"key":"1355_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/S-0043-116492\/ID\/R2017-05-0662-0017\/BIB","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:9\u201362. https:\/\/doi.org\/10.1055\/S-0043-116492\/ID\/R2017-05-0662-0017\/BIB","journal-title":"Pharmacopsychiatry"},{"key":"1355_CR15","unstructured":"IADB.nl (2022) IADB.nl Drug use research. https:\/\/iadb.nl\/. Accessed 11 Sep 2022"},{"key":"1355_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.18773\/AUSTPRESCR.2016.039","volume":"39","author":"N Keks","year":"2016","unstructured":"Keks N, Hope J, Keogh S (2016) Switching and stopping antidepressants. Aust Prescr 39:76. https:\/\/doi.org\/10.18773\/AUSTPRESCR.2016.039","journal-title":"Aust Prescr"},{"key":"1355_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/S11920-010-0114-X","volume":"12","author":"DR Kim","year":"2010","unstructured":"Kim DR, O\u2019Reardon JP, Epperson CN (2010) Guidelines for the management of depression during pregnancy. Curr Psychiatry Rep 12:279. https:\/\/doi.org\/10.1007\/S11920-010-0114-X","journal-title":"Curr Psychiatry Rep"},{"key":"1355_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/J.JAD.2019.12.014","volume":"264","author":"NM Molenaar","year":"2020","unstructured":"Molenaar NM, Bais B, Lambregtse-van den Berg MP et al (2020a) The international prevalence of antidepressant use before, during, and after pregnancy: a systematic review and meta-analysis of timing, type of prescriptions and geographical variability. J Affect Disord 264:82\u201389. https:\/\/doi.org\/10.1016\/J.JAD.2019.12.014","journal-title":"J Affect Disord"},{"key":"1355_CR19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1177\/0004867418762057","volume":"52","author":"NM Molenaar","year":"2018","unstructured":"Molenaar NM, Kamperman AM, Boyce P, Bergink V (2018) Guidelines on treatment of perinatal depression with antidepressants: an international review. Aust N Z J Psychiatry 52:320. https:\/\/doi.org\/10.1177\/0004867418762057","journal-title":"Aust N Z J Psychiatry"},{"key":"1355_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00737-019-0951-5","volume":"23","author":"NM Molenaar","year":"2020","unstructured":"Molenaar NM, Lambregtse-van den Berg MP, Bonsel GJ (2020b) Dispensing patterns of selective serotonin reuptake inhibitors before, during and after pregnancy: a 16-year population-based cohort study from the Netherlands. Arch Womens Ment Health 23:71\u201379. https:\/\/doi.org\/10.1007\/s00737-019-0951-5","journal-title":"Arch Womens Ment Health"},{"key":"1355_CR21","unstructured":"Zorginstituut Nederland (2022a) Anxiety disorders. https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/indicatieteksten\/angststoornissen. Accessed 28 Feb 2023"},{"key":"1355_CR22","unstructured":"Zorginstituut Nederland (2022b) Depression. https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/indicatieteksten\/depressie#depressie_behandelplan_2. Accessed 28 Feb 2023"},{"key":"1355_CR23","unstructured":"Zorginstituut Nederland (2022c) Sertraline. https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/preparaatteksten\/s\/sertraline#doseringen. Accessed 11 Sep 2022"},{"key":"1355_CR24","unstructured":"Zorginstituut Nederland (2022d) Bupropion. https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/preparaatteksten\/b\/bupropion#indicaties. Accessed 11 Sep 2022"},{"key":"1355_CR25","unstructured":"NVOG (2012) SSRI and pregnancy | Richtlijnen Database. https:\/\/richtlijnendatabase.nl\/richtlijn\/ssri_en_zwangerschap\/ssri-gebruik_en_zwangerschap_-_startpagina.html. Accessed 11 Sep 2022"},{"key":"1355_CR26","unstructured":"NVOG (2021) Antipsychotics and non-SSRI antidepressants during pregnancy and lactation | Richtlijnen Database. https:\/\/richtlijnendatabase.nl\/richtlijn\/antipsychotica_en_niet-ssri_antidepressiva_tijdens_zwangerschap_en_lactatie\/startpagina_-_antipsychotica_en_niet-ssri_antidepressiva_tijdens_zwangerschap_en_lactatie.html. Accessed 11 Sep 2022"},{"key":"1355_CR27","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3889\/oamjms.2019.270","volume":"7","author":"HI Okagbue","year":"2019","unstructured":"Okagbue HI, Adamu PI, Bishop SA et al (2019) Systematic review of prevalence of antepartum depression during the trimesters of pregnancy. Open Access Maced J Med Sci 7:1555. https:\/\/doi.org\/10.3889\/oamjms.2019.270","journal-title":"Open Access Maced J Med Sci"},{"key":"1355_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jclinepi.2002.12.001","volume":"57","author":"E Schirm","year":"2004","unstructured":"Schirm E, Tobi H, Den Berg DJ-V (2004) Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. J Clin Epidemiol 57:737\u2013741. https:\/\/doi.org\/10.1016\/j.jclinepi.2002.12.001","journal-title":"J Clin Epidemiol"},{"key":"1355_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/17425255.2020.1750598","volume":"16","author":"G Schoretsanitis","year":"2020","unstructured":"Schoretsanitis G, Spigset O, Stingl JC et al (2020) The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol 16:431. https:\/\/doi.org\/10.1080\/17425255.2020.1750598","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1355_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2147\/CLEP.S163037","volume":"10","author":"R Sediq","year":"2018","unstructured":"Sediq R, van der Schans J, Dotinga A et al (2018) Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort study with the pharmacy database iaDB.nl: the PharmLines initiative. Clin Epidemiol 10:981\u2013989. https:\/\/doi.org\/10.2147\/CLEP.S163037","journal-title":"Clin Epidemiol"},{"key":"1355_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4088\/JCP.V69N0419","volume":"69","author":"DK Sit","year":"2008","unstructured":"Sit DK, Perel JM, Helsel JC, Wisner KL (2008) Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 69:652\u2013658. https:\/\/doi.org\/10.4088\/JCP.V69N0419","journal-title":"J Clin Psychiatry"},{"key":"1355_CR32","unstructured":"Stichting Health Base (2020) Commentaren Medicatiebewaking 2001-2020. https:\/\/www.commentarenmedicatiebewaking.nl\/. Accessed 10 Mar 2022"},{"key":"1355_CR33","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.2147\/CLEP.S379370","volume":"14","author":"NT Trinh","year":"2022","unstructured":"Trinh NT, Nordeng HM, Bandoli G et al (2022) Antidepressant fill and dose trajectories in pregnant women with depression and\/or anxiety: a Norwegian Registry Linkage Study. Clin Epidemiol 14:1439\u20131451. https:\/\/doi.org\/10.2147\/CLEP.S379370","journal-title":"Clin Epidemiol"},{"key":"1355_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1586\/erp.13.20","volume":"13","author":"ST Visser","year":"2013","unstructured":"Visser ST, Schuiling-Veninga CC, Bos JH et al (2013) The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res 13:285\u2013292. https:\/\/doi.org\/10.1586\/erp.13.20","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1355_CR35","unstructured":"WHOCC (2022a) WHOCC - ATC\/DDD Index. https:\/\/www.whocc.no\/atc_DDD_index\/?code=N06A&showdescription=no. Accessed 11 Sep 2022"},{"key":"1355_CR36","unstructured":"WHOCC (2022b) WHOCC - ATC\/DDD Index. https:\/\/www.whocc.no\/atc_DDD_index\/?code=N06AB06. Accessed 21 Feb 2023"},{"key":"1355_CR37","doi-asserted-by":"publisher","unstructured":"Zoega H, Kieler H, Norgaard M et al (2015) Use of SSRI and SNRI antidepressants during pregnancy: a population-based study from Denmark, Iceland, Norway and Sweden. PLoS One 10. https:\/\/doi.org\/10.1371\/journal.pone.0144474","DOI":"10.1371\/journal.pone.0144474"}],"container-title":["Archives of Women's Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-023-01355-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00737-023-01355-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-023-01355-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T05:03:39Z","timestamp":1694149419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00737-023-01355-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1355"],"URL":"https:\/\/doi.org\/10.1007\/s00737-023-01355-8","relation":{},"ISSN":["1434-1816","1435-1102"],"issn-type":[{"value":"1434-1816","type":"print"},{"value":"1435-1102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,5]]},"assertion":[{"value":"23 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Under Dutch law, subject consent or approval from an Ethics Committee is not required for anonymized healthcare data for pharmacoepidemiological research. The database complies with the European data protection law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}